Particle.news
Medication Adherence Covid Vaccines Funding Clinical Trials Pharmaceutical Industry Research Studies Pharmacology Earnings Reports Corporate Strategy Investment
Amgen plans a 72-week pivotal study following phase 2 results that showed substantial weight loss alongside lower gastrointestinal side effects from a low-dose ramp-up.
